登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07674524,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed locally advanced [defined as Stage IIIB/C per AJCC v7.0 and not amenable to multimodality treatment] or metastatic (Stage IV) ALK-positive NSCLC; ALK status must be confirmed by Ventana ALK (D5F3) Companion Diagnostic (CDx) IHC (Ventana ULTRA or XT platform), FISH, PCR, next-generation sequencing (NGS), or circulating tumor DNA (ctDNA) testing;
入选标准第 2 条
Chronic kidney disease (CKD) stage 3-4;
入选标准第 23 条
Major surgery within 4 weeks prior to randomization; minor surgery (e.g., port placement) is permitted provided the incision is adequately healed
排除标准第 8 条
Radiotherapy within 2 weeks prior to enrollment, including stereotactic or partial brain radiotherapy. Patients who complete whole brain radiotherapy within 4 weeks prior to randomization, or palliative radiotherapy outside the CNS within 48 hours prior to randomization, are also excluded
排除标准第 9 条
Gastrointestinal abnormalities including: inability to take oral medication; need for parenteral nutrition; prior surgery affecting absorption (e.g., total gastrectomy, gastric banding); active inflammatory bowel disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer within the past 6 months; malabsorption syndrome
排除标准第 10 条
Active malignancy within 3 years prior to randomization (excluding NSCLC, non-melanoma skin cancer, localized prostate cancer not requiring immediate treatment, or any carcinoma in situ)
排除标准第 13 条
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2;
入选标准第 5 条
Hyperlipidemia during first-line lorlatinib treatment, with ULN ≤ TC < 12.93 mmol/L (Grade 1-3);
入选标准第 7 条
At least one measurable target lesion per RECIST v1.1, not previously irradiated; brain metastases are allowed;
入选标准第 3 条
Negative serum pregnancy test at screening for women of childbearing potential. Non-childbearing potential must meet at least one of the following:
入选标准第 9 条
Pregnant or lactating women, or fertile individuals (male or female) unwilling to use effective contraception during the study
排除标准第 6 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07674524,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Diagnosis: Histologically or cytologically confirmed locally advanced [defined as Stage IIIB/C per AJCC v7.0 and not amenable to multimodality treatment] or metastatic (Stage IV) ALK-positive NSCLC; ALK status must be confirmed by Ventana ALK (D5F3) Companion Diagnostic (CDx) IHC (Ventana ULTRA or XT platform), FISH, PCR, next-generation sequencing (NGS), or circulating tumor DNA (ctDNA) testing; At least one measurable target lesion per RECIST v1.1, not previously irradiated; brain metastases are allowed; No prior systemic therapy for advanced (Stage IIIB/C not amenable to multimodality treatment) or metastatic (Stage IV) disease; Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2; Age ≥ 18 years; Hyperlipidemia during first-line lorlatinib treatment, with ULN ≤ TC < 12.93 mmol/L (Grade 1-3); Life expectancy ≥ 6 months; Negative serum pregnancy test at screening for women of childbearing potential. Non-childbearing potential must meet at least one of the following: Postmenopausal status: regular menstrual cessation ≥ 12 months with no other pathological or physiological cause (serum FSH level may be used to confirm postmenopausal status, if applicable); Hysterectomy and/or bilateral oophorectomy; Medically confirmed ovarian failure; All other women (including those with tubal ligation) are considered of childbearing potential; Provide signed and dated informed consent from the patient (or legal representative), indicating full understanding of the study-related information. Acute coronary syndrome (ACS) within the past 1 year; History of myocardial infarction (excluding recent ACS); History of ischemic stroke; Symptomatic peripheral artery disease (PAD), including prior revascularization or amputation. Premature coronary artery disease (male < 55 years; female < 65 years); Familial hypercholesterolemia; History of coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI); Diabetes mellitus; Hypertension; Chronic kidney disease (CKD) stage 3-4; Current smoker. -排除标准:Exclusion Criteria:
Mixed squamous cell carcinoma, large cell carcinoma, or small cell lung cancer Prior systemic anticancer therapy for NSCLC, including chemotherapy, biologic therapy, immunotherapy, or any investigational drug Diagnosed genetic hypercholesterolemia (e.g., familial hypercholesterolemia, Part A only) or secondary dyslipidemia with a clear etiology (e.g., hypothyroidism, uncontrolled diabetes, nephrotic syndrome) Known allergy or history of severe adverse reaction to any study drug (including lorlatinib, statins, ezetimibe, or evolocumab) Presence of other severe diseases that may affect study compliance or outcome assessment, including advanced renal failure (eGFR < 30 mL/min/1.73 m²) or severe hepatic impairment (Child-Pugh Class C) Pregnant or lactating women, or fertile individuals (male or female) unwilling to use effective contraception during the study Currently participating in another interventional clinical study that may interfere with this study; patients expected to be unable to complete follow-up or the first tumor efficacy assessment; patients with mental or psychological disorders who cannot provide informed consent or comply with study requirements (including treatment and follow-up) Major surgery within 4 weeks prior to randomization; minor surgery (e.g., port placement) is permitted provided the incision is adequately healed Radiotherapy within 2 weeks prior to enrollment, including stereotactic or partial brain radiotherapy. Patients who complete whole brain radiotherapy within 4 weeks prior to randomization, or palliative radiotherapy outside the CNS within 48 hours prior to randomization, are also excluded Gastrointestinal abnormalities including: inability to take oral medication; need for parenteral nutrition; prior surgery affecting absorption (e.g., total gastrectomy, gastric banding); active inflammatory bowel disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer within the past 6 months; malabsorption syndrome Known or suspected severe hypersensitivity to the study drug or any of its excipients History of extensive, disseminated, or bilateral disease, or current Grade 3-4 interstitial fibrosis/interstitial lung disease, including but not limited to: pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, bronchiolitis obliterans, and pulmonary fibrosis Active malignancy within 3 years prior to randomization (excluding NSCLC, non-melanoma skin cancer, localized prostate cancer not requiring immediate treatment, or any carcinoma in situ) Concurrent use within 12 days prior to first lorlatinib dose of: Strong CYP3A inhibitors (e.g., grapefruit juice or grapefruit/related citrus fruits [Seville oranges, pomelos]; boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole; ritonavir alone or with danoprevir, elvitegravir, indinavir, lopinavir, paritaprevir, ombitasvir, dasabuvir, saquinavir, tipranavir; telaprevir, troleandomycin, voriconazole. Topical use such as 2% ketoconazole cream is permitted where applicable) Known narrow therapeutic index CYP3A substrates (e.g., astemizole, terfenadine, cisapride, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl [including transdermal patch], or ergot alkaloids [ergotamine, dihydroergotamine]) (withdrawn from U.S. market) Known strong CYP3A inducers (e.g., carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort) Known narrow therapeutic index P-gp substrates (e.g., digoxin) Other severe acute or chronic medical or psychiatric conditions, including suicidal ideation or behavior within the past 1 year, that may increase the risk of study participation or study drug use, or laboratory abnormalities that may interfere with interpretation of study results, and patients deemed by the investigator to be unsuitable for enrollment Participation in another investigational drug study within 2 weeks prior to enrollment and/or during the study period
引自 ClinicalTrials.gov, NCT07674524, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07674524,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。